Page last updated: 2024-12-06

mmda

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MMDA: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26175
CHEMBL ID126506
SCHEMBL ID1739571
MeSH IDM0052469

Synonyms (43)

Synonym
1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl
brn 1246630
3-methoxy-4,5-methylenedioxyphenylisopropylamine
phenethylamine, alpha-methyl-3-methoxy-4,5-(methylenedioxy)-
3-methoxy-alpha-methyl-4,5-methylenedioxyphenethylamine
beta-methoxy-alpha-methyl-4,5-(methylenedioxy)phenethyl amine
13674-05-0
1,3-benzodioxole-5-ethanamine, 7-methoxy-a-methyl- (9ci)
5-methoxy-3,4-methylenedioxyamphetamine
dea no. 7401
(+-)-mmda
mmda
phenethylamine, 3-methoxy-alpha-methyl-4,5-(methylenedioxy)-
1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl-
1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl (9ci)
amphetamine, 3,4-methylenedioxy-5-methoxy
3-methoxy-methylenedioxyamphetamine
DB01442
CHEMBL126506
1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-ylazanium chloride
1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
rg7fy73zaa ,
unii-rg7fy73zaa
mmda (drug)
SCHEMBL1739571
phenethylamine, 3-methoxy-.alpha.-methyl-4,5-(methylenedioxy)-
(.+/-.)-mmda
phenethylamine, .alpha.-methyl-3-methoxy-4,5-(methylenedioxy)-
2-(7-methoxy-1,3-benzodioxol-5-yl)-1-methylethylamine
3-methoxy-4,5-methylenedioxyamphetamine
1,3-benzodioxole-5-ethanamine, 7-methoxy-a-methyl-
3-methoxy-.alpha.-methyl-4,5-methylenedioxyphenethylamine
YQYUWUKDEVZFDB-UHFFFAOYSA-N
5-methoxy-mda
3-methoxy-alpha-methyl-4,5-(methylenedioxy)phenethylamine
.beta.-methoxy-.alpha.-methyl-4,5-(methylenedioxy)phenethyl amine
mmda (psychedelic)
(+/-)-mmda
3-methoxy-.alpha.-methyl-4,5-(methylenedioxy)phenethylamine
(+/-)-5-methoxy-3,4-methylenedioxyamphetamine
Q4030702
DTXSID50860757
1-(7-methoxy-2h-1,3-benzodioxol-5-yl)propan-2-amine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" MMDA supplementation significantly reduced the deposition of AFB1, T2-toxin and their metabolites in liver and kidneys at the maximum tolerated dosage (2 and 3 g/kg) indicating specific binding to AFB1 and T2-toxin in the digestive tract as compared to the corresponding diets without MMDA."( Effects of supplemented multicomponent mycotoxin detoxifying agent in laying hens fed aflatoxin B1 and T2-toxin contaminated feeds.
Asrani, RK; Farkaš, H; Jakovčević, Z; Kumar, R; Raj, J; Vasiljević, M, 2023
)
1.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID1131956Hallucinogenic activity in human1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID178403Effective dose in rats trained on 1 mg/kg DOM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's4 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (8.33)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.25 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index143.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]